These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 17804674

  • 1. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
    Diekmann F, Rovira J, Carreras J, Arellano EM, Bañón-Maneus E, Ramírez-Bajo MJ, Gutiérrez-Dalmau A, Brunet M, Campistol JM.
    J Am Soc Nephrol; 2007 Oct; 18(10):2653-60. PubMed ID: 17804674
    [Abstract] [Full Text] [Related]

  • 2. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
    Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W.
    J Am Soc Nephrol; 2005 Jul; 16(7):2063-72. PubMed ID: 15917339
    [Abstract] [Full Text] [Related]

  • 3. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C.
    Transplantation; 2007 Dec 15; 84(11):1492-9. PubMed ID: 18091526
    [Abstract] [Full Text] [Related]

  • 4. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
    Ko HT, Yin JL, Wyburn K, Wu H, Eris JM, Hambly BD, Chadban SJ.
    Nephrol Dial Transplant; 2013 Feb 15; 28(2):327-36. PubMed ID: 23229928
    [Abstract] [Full Text] [Related]

  • 5. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
    Krämer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H.
    Am J Physiol Renal Physiol; 2008 Feb 15; 294(2):F440-9. PubMed ID: 18094032
    [Abstract] [Full Text] [Related]

  • 6. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N, Torras J, Alperovich G, Cruzado JM, Giménez-Bonafé P, Herrero-Fresneda I, Franquesa Ml, Rama I, Grinyó JM.
    Nephrol Dial Transplant; 2008 Oct 15; 23(10):3111-9. PubMed ID: 18469305
    [Abstract] [Full Text] [Related]

  • 7. Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction.
    Rovira J, Arellano EM, Carreras J, Campos B, Vodenik B, Bañón-Maneus E, Ramírez-Bajo MJ, Moya-Rull D, Solé-González A, Hernández A, Revuelta I, Quintana LF, Howat WJ, Campistol JM, Diekmann F.
    Transplantation; 2009 Sep 15; 88(5):646-52. PubMed ID: 19741461
    [Abstract] [Full Text] [Related]

  • 8. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
    Keller K, Daniel C, Schöcklmann H, Endlich KH, Kerjaschki D, Johnson RJ, Hugo C.
    Nephrol Dial Transplant; 2006 Oct 15; 21(10):2724-35. PubMed ID: 16861242
    [Abstract] [Full Text] [Related]

  • 9. Vascular endothelial growth factor in chronic rat allograft nephropathy.
    Malmström NK, Kallio EA, Rintala JM, Nykänen AI, Räisänen-Sokolowski AK, Paavonen T, Lemström KB, Koskinen PK.
    Transpl Immunol; 2008 May 15; 19(2):136-44. PubMed ID: 18503889
    [Abstract] [Full Text] [Related]

  • 10. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
    Torras J, Herrero-Fresneda I, Gulias O, Flaquer M, Vidal A, Cruzado JM, Lloberas N, Franquesa Ml, Grinyó JM.
    Nephrol Dial Transplant; 2009 Dec 15; 24(12):3632-40. PubMed ID: 19671594
    [Abstract] [Full Text] [Related]

  • 11. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
    Letavernier E, Legendre C.
    Transplant Rev (Orlando); 2008 Apr 15; 22(2):125-30. PubMed ID: 18631865
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP.
    Nephrol Dial Transplant; 2006 Mar 15; 21(3):598-604. PubMed ID: 16221708
    [Abstract] [Full Text] [Related]

  • 13. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, improved renal microvascular insufficiency in 5/6 nephrectomized rats.
    Song J, Meng L, Li S, Qu L, Li X.
    Vascul Pharmacol; 2009 Mar 15; 50(5-6):185-93. PubMed ID: 19563735
    [Abstract] [Full Text] [Related]

  • 14. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration.
    Saurina A, Campistol JM, Lario S, Oppenheimer F, Diekmann F.
    Transplant Proc; 2007 Sep 15; 39(7):2138-41. PubMed ID: 17889117
    [Abstract] [Full Text] [Related]

  • 15. Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis.
    Rangan GK, Coombes JD.
    Nephrol Dial Transplant; 2007 Aug 15; 22(8):2175-82. PubMed ID: 17550925
    [Abstract] [Full Text] [Related]

  • 16. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL.
    Am J Physiol Renal Physiol; 2009 Dec 15; 297(6):F1597-605. PubMed ID: 19776171
    [Abstract] [Full Text] [Related]

  • 17. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun 15; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 18. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 15; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C.
    IUBMB Life; 2007 Nov 15; 59(11):717-21. PubMed ID: 17968710
    [Abstract] [Full Text] [Related]

  • 20. Expression and mechanism of mammalian target of rapamycin in age-related renal cell senescence and organ aging.
    Zhuo L, Cai G, Liu F, Fu B, Liu W, Hong Q, Ma Q, Peng Y, Wang J, Chen X.
    Mech Ageing Dev; 2009 Oct 15; 130(10):700-8. PubMed ID: 19698731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.